Efficacy of Local Instillation of Recombinant Tissue Plasminogen Activator for Restoring Occluded Central Venous Catheters in Neonates

Journal of Pediatrics

Volumn 156, Issue 2, 2010, Pages

  Soylu, Hanifi ^a   Brandão, Leonardo R ^b   Lee, Kyong Soon ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ARTICLE; BACTEREMIA; BIRTH WEIGHT; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CATHETER OCCLUSION; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EMBOLISM; FEMALE; GESTATIONAL AGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; NEWBORN; NEWBORN INTENSIVE CARE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SEPTICEMIA; THROMBOSIS;

EID: 74649086833     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2009.09.007     Document Type: Article

References (32)

1. Haas N.A., and Haas S.A. Central venous catheter techniques in infants and children. Curr Opin Anaesthesiol 16 (2003) 291-303
2. Ainsworth S.B., Clerihew L., and McGuire W. Percutaneous central venous catheters versus peripheral cannulae for delivery of parenteral nutrition in neonates. Cochrane Database Syst Rev 3 (2007) CD004219
3. Hermansen M.C., and Hermansen M.G. Intravascular catheter complications in the neonatal intensive care unit. Clin Perinatol 32 (2005) 141-156
4. Paulson P.R., and Miller K.M. Neonatal peripherally inserted central catheters: recommendations for prevention of insertion and postinsertion complications. Neonatal Netw 27 (2008) 245-257
5. Beardsall K., White D.K., Pinto E.M., and Kelsall A.W. Pericardial effusion and cardiac tamponade as complications of neonatal long lines: are they really a problem?. Arch Dis Child Fetal Neonatal Ed 88 (2003) F292-F295
6. Benjamin Jr. D.K., Miller W., Garges H., Benjamin D.K., McKinney Jr. R.E., Cotton M., Fisher R.G., and Alexander K.A. Bacteremia, central catheters, and neonates: when to pull the line. Pediatrics 107 (2001) 1272-1276
7. Monagle P., Chalmers E., Chan A., deVeber G., Kirkham F., Massicotte P., and Michelson A.D. Antithrombotic therapy in neonates and children. Chest 133 (2008) 887S-968S
8. Important drug warning regarding the use of Abbokinase (urokinase) (1999), US Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD 208-1448
9. Hartmann J., Hussein A., Trowitzsch E., Becker J., and Hennecke K.H. Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature. Arch Dis Child Fetal Neonatal Ed 85 (2001) F18-F22
10. Atkinson J.B., Bagnall H.A., and Gomperts E. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters. JPEN J Parenter Enteral Nutr 14 (1990) 310-311
11. Gupta A.A., Leaker M., Andrew M., Massicotte P., Liu L., Benson L.N., and McCrindle B.W. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 139 (2001) 682-688
12. Levy M., Benson L.N., Burrows P.E., Bentur Y., Strong D.K., Smith J., Johnson D., Jacobson S., and Koren G. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr 118 (1991) 467-472
13. Davis S.N., Vermeulen L., Banton J., Schwartz B.S., and Williams E.C. Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices. Am J Health Syst Pharm 57 (2000) 1039-1045
14. Chandler W.L., Alessi M.C., Aillaud M.F., Henderson P., Vague P., and Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 96 (1997) 761-768
15. Ponec D., Irwin D., Haire W.D., Hill P.A., Li X., and McCluskey E.R. COOL Investigators. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial: the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 12 (2001) 951-955
16. Semba C.P., Deitcher S.R., Li X., Resnansky L., Tu T., and McCluskey E.R. Cardiovascular Thrombolytic to Open Occluded Lines Investigators. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients. J Vasc Interv Radiol 13 (2002) 1199-1205
17. Blaney M., Shen V., Kerner J., Jacobs B.R., Gray S., Armfield J., and Semba C.P. CAPS Investigators. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (the Cathflo Activase Pediatric Study). J Vasc Interv Radiol 17 (2006) 1745-1751
18. Shen V., Li X., Murdock M., Resnansky L., McCluskey E.R., and Semba C.P. COOL Investigators. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr Hematol Oncol 25 (2003) 38-45
19. Kleta R., Schleef J., and Jürgens H. Tissue plasminogen activator and obstructed central venous catheters. Med Pediatr Oncol 30 (1998) 376
20. Choi M., Massicotte M.P., Marzinotto V., Chan A.K., Holmes J.L., and Andrew M. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. J Pediatr 139 (2001) 152-156
21. Jacobs B.R., Haygood M., and Hingl J. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children. J Pediatr 139 (2001) 593-596
22. Chesler L., and Feusner J.H. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters. J Pediatr Hematol Oncol 24 (2002) 653-656
23. Fisher A.A., Deffenbaugh C., Poole R.L., Garcia M., and Kerner Jr. J.A. The use of alteplase for restoring patency to occluded central venous access devices in infants and children. J Infus Nurs 27 (2004) 171-174
24. Ng R., Li X., Tu T., and Semba C.P. Alteplase for treatment of occluded peripherally inserted central catheters: safety and efficacy in 240 patients. J Vasc Interv Radiol 15 (2004) 45-49
25. Zenz W., Arl F., Sodia S., and Berghold A. Intracerebral hemorrhage during fibrinolytic therapy in children: a review of the literature of the last thirty years. Semin Thromb Hemost 23 (1997) 321-332
26. Parmar N., Mitchell L.G., Berry L.R., Andrew M., and Chan A.K.C. The influence of age on in vitro plasmin generation in the presence of fibrin monomer. Acta Haematol 115 (2006) 141-151
27. Lee E.K. Alteplase use for prevention of central line occlusion in a preterm infant. Ann Pharmacother 36 (2002) 272-274
28. Mehta S., Connors Jr. A.F., Danish E.H., and Grisoni E. Incidence of thrombosis during central venous catheterization of newborns: a prospective study. J Pediatr Surg 27 (1992) 18-22
29. Schiff D.E., and Stonestreet B.S. Central venous catheters in low birth weight infants: incidence of related complications. J Perinatol 13 (1993) 153-158
30. Clinicath PolyFlow Polyurethane Peripherally Inserted Catheter. Instructions for use. Smiths Medical MD, Inc St Paul, MN. 2007.
31. Kerner Jr. J.A., Garcia-Careaga M.G., Fisher A.A., and Poole R.L. Treatment of catheter occlusion in pediatric patients. JPEN J Parenter Enteral Nutr 30 (2006) S73-S81
32. Wang M., Hays T., Balasa V., Bagatell R., Gruppo R., Grabowski E.F., Valentino L.A., Tsao-Wu G., and Manco-Johnson M.J. Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol Oncol 25 (2003) 379-386